Young survivors of severe brain hemorrhage have an elevated risk of suicide: more attention needs to be paid to psychological rehabilitation
20.1.2025 13:56:00 EET | HUS | Press release
A nationwide Finnish study conducted at HUS Neurosurgery revealed that survivors of life-threatening brain hemorrhage have a significantly elevated risk of suicide. The risk is especially higher in patients under the age of 40 and those with a recent brain hemorrhage.

Subarachnoid hemorrhage (SAH) is a life-threatening cerebrovascular disorder where the rupture of a bulging blood vessel, called an aneurysm, causes bleeding in the brain. Today, more and more patients with SAH survive and make a good physical recovery, but at least one third of all affected patients suffer from depression and anxiety.
A study by researchers from HUS and University of Helsinki published in the journal Neurology investigated the risk of suicide in Finland over two decades among patients who survived SAH for at least one month after their illness. The study included more than 5,700 patients.
The results show that SAH survivors have about 75 percent higher risk of suicide in comparison with the general Finnish population of the same age and sex. A particularly elevated risk, almost four times higher, was observed in young survivors aged 15 to 39. Moreover, the first year post-SAH appeared to be a particularly high-risk period for suicide.
Physical recovery alone is not enough
“It is worrying that as many as 14 percent of deaths among young SAH survivors were due to suicide. The increased risk of suicide seems to be higher following a SAH than after other cerebrovascular disorders, namely cerebral infarction and intracerebral hemorrhage,” says Aleksanteri Asikainen, Bachelor of Medicine and Ph.D. student from the University of Helsinki.
The link between SAH and elevated risk of suicide is thought to be due to a sudden decline in physical and cognitive function, which increases psychological distress and exacerbates existing mental health disorders. In young, often healthy, individuals, the consequences of SAH are likely to be more evident in everyday life than in the general population.
The other members of the research group, HUS Neurosurgeon and Associate Professor Miikka Korja, Professor of Genetic Epidemiology from the University of Helsinki Jaakko Kaprio, and Physician Specializing in Neurosurgery at HUS and Associate Professor Ilari Rautalin stress the need for further research to more precisely identify risk factors that influence the suicide risk and to develop rehabilitation measures to support patients.
“Our study underlines that physical recovery alone is not enough. It is more important than ever to identify patients' psychological support needs and to intervene early in mental health issues to prevent consequences that can significantly reduce quality of life and even be life-threatening," says Rautalin, the senior author of the article.
Research article: Asikainen A, Korja M, Kaprio J, Rautalin I. Risk of Suicide After Aneurysmal Subarachnoid Hemorrhage: A Nationwide Study
The study was published online in the journal Neurology on January 15, 2025.
In a university hospital, research is part of the treatment: we continuously evaluate and develop care based on scientific research evidence and patient experience. At HUS, we conduct close research collaboration with the Faculty of Medicine at the University of Helsinki. We publish approximately 2,400 peer-reviewed research articles) annually, which we highlight in our newsfeed.
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Keywords
Contacts
Bachelor of Medicine, Ph.D. Student Aleksanteri Asikainen,
HUS Neurocenter, Neurosurgery and University of Helsinki
aleksanteri.asikainen@helsinki.fi
Specialist in Neurosurgery, Associate Professor Miikka Korja
HUS Neurocenter, Neurosurgery and University of Helsinki
miikka.korja@hus.fi
Specializing Physician in Neurosurgery, Associate Professor Ilari Rautalin,
HUS Neurocenter, Neurosurgery and University of Helsinki
ilari.rautalin@helsinki.fi
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Studie gav ny kunskap om immunförsvaret vid leukemi29.9.2026 08:26:54 EEST | Pressmeddelande
Forskare vid HUS Cancercentrum och Helsingfors universitet utredde hur immunsystemet hos patienter med akut myeloisk leukemi reagerade på experimentell immunterapi. Förändringar som hänför sig till terapiresponsen visade sig i andra immunceller än förväntat baserat på tidigare studier.
Tutkimus toi uutta tietoa leukemian immuunipuolustuksesta29.9.2026 08:26:54 EEST | Tiedote
HUSin Syöpäkeskuksen ja Helsingin yliopiston tutkijat selvittivät, miten akuuttia myelooista leukemiaa sairastavien potilaiden immuunijärjestelmä reagoi kokeelliseen immunoterapiaan. Hoitovasteeseen liittyvät muutokset näkyivät eri immuunisoluissa kuin aiempien tutkimusten perusteella olisi voitu odottaa.
Study provides new insights into the immune response in leukemia29.9.2026 08:26:54 EEST | Press release
Researchers at HUS Comprehensive Cancer Center and the University of Helsinki investigated how the immune systems of patients with acute myeloid leukemia (AML) respond to experimental immunotherapy. The study found that changes associated with treatment response were observed in different immune cell types than would have been expected based on previous research.
Genetiska undersökningar kan avslöja orsaken till plötslig oförklarlig död hos unga14.9.2026 09:18:15 EEST | Pressmeddelande
Den bakomliggande orsaken till plötslig oförklarlig död hos unga kan vara en sällsynt ärftlig sjukdom som nödvändigtvis inte kommer fram i vanliga undersökningar. Genetiska undersökningar är en viktig del särskilt i utredningen av plötsliga oväntade dödsfall hos unga. Genetiska undersökningar kan också bidra till att identifiera släktingar som omfattas av risken och förebygga eventuella allvarliga hjärthändelser.
Geenitutkimus voi paljastaa syyn nuoren selittämättömälle äkkikuolemalle14.9.2026 09:18:15 EEST | Tiedote
Nuoren selittämättömän äkkikuoleman taustalla voi olla harvinainen perinnöllinen sairaus, joka ei välttämättä tule esiin tavanomaisissa tutkimuksissa. Geenitutkimus on tärkeä osa erityisesti nuorten odottamattomien äkkikuolemien syyn selvittämisessä. Geenitutkimus voi myös auttaa tunnistamaan riskissä olevia sukulaisia ja ehkäistä mahdollisia vakavia sydäntapahtumia.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom